The investigational orexin receptor 2 (OX2R) agonist oveporexton improved cognitive symptoms of narcolepsy type 1 (NT1) in secondary analysis of a phase II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback